EPS Creative Health Technology Group Limited provides earning guidance for the six months ended September 30, 2021. For the period, the Group is expected to record a loss attributable to Shareholders for the six months ended 30 September 2021 in the range of HKD 4 million to HKD 6 million, as compared to a profit attributable to Shareholders of approximately HKD 4.4 million for the corresponding period in 2020. Such loss is mainly attributable to (i) the expenses incurred in relation to new drug development projects; and (ii) the expenses incurred by the Company in response to the unconditional mandatory cash offer as a result of the change of control of the Company disclosed in the Company's announcement dated 5 May, 2021. Despite the above, the Group's financial position remains strong.